The effectiveness of the anti-tumor necrosis factor therapy infliximab in neuro-Behcet's disease: a systematic review and meta-analysis

ObjectiveTo study the effectiveness of infliximab for the treatment of refractory central neuro-Behcet's disease. MethodsIn this systematic review and meta-analysis, the research question was designed using the 'Population, Intervention, Comparator, and Outcomes' (PICO) model and the search methodology was developed according to the PRISMA statement. The study was registered on PROSPERO. Web of Science, PubMed, and Cochrane Library databases were searched for articles published in English between January 2000 and January 2020. Data were analysed using Meta-Essentials software, version 10.12. Treatment effect size was determined by a random effects model. Interstudy heterogeneity was explored using I-2 statistics. Cumulative meta-analysis was conducted to assess the temporal trend for accumulating evidence. ResultsTwenty-one studies, comprising 64 patients (mean age, 38 .21 years and mean disease duration, 84.76 months) were included. Effect-size analysis showed that 93.7% of the treated patients in the analysis were responders to infliximab therapy (95% confidence interval 0.88, 0.993). There was no significant inter-study heterogeneity (I-2 = 0%). Cumulative analysis showed accumulating evidence favoring increasing effectiveness over the last 20 years. ConclusionInfliximab showed considerable therapeutic effectiveness in the treatment of refractory neuro-Behcet's disease.